Cytomedix, Inc. (CMXI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Cytomedix, Inc. (Cytomedix) is an integrated regenerative medicine company that develops and commercializes innovative platelet and adult stem cell separation products that boosts the body's natural healing processes. Cytomedix’s advanced autologous technologies provide clinicians a new treatment paradigm for wound and tissue repair. The company’s commercial products include AutoloGel System for wound care and the Angel Whole Blood Separation System. Also, Cytomedix is developing novel regenerative therapies using its proprietary ALDH Bright Cell technology to isolate an exclusive, biologically active population of a patient’s own stem cells.
Cytomedix, Inc. Key Recent Developments
Apr 07, 2014: Cytomedix Announces Appointment of Andrew Cohen as Vice President of Marketing
Apr 03, 2014: Cytomedix Announces Receipt of USPTO Allowance for Patent Covering Use of ALDH Bright Cells in Stroke
Mar 31, 2014: Cytomedix Reports 2013 Fourth Quarter and Full Year Financial Results
Mar 31, 2014: Cytomedix Announces Senior Management Appointments
Nov 12, 2013: Cytomedix Reports Third Quarter 2013 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Cytomedix, Inc. - Key Facts 5
Cytomedix, Inc. - Key Employees 6
Cytomedix, Inc. - Key Employee Biographies 7
Cytomedix, Inc. - Major Products and Services 8
Cytomedix, Inc. - Pharmaceutical Pipeline Products Data 9
Cytomedix, Inc., Pipeline Products by Therapy Area 9
Cytomedix, Inc., Pipeline Products by Development Phase 10
Cytomedix, Inc. Pipeline Products by Development Stage 13
Cytomedix, Inc. - History 15
Cytomedix, Inc. - Company Statement 17
Cytomedix, Inc. - Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Section 2 – Company Analysis 25
Cytomedix, Inc. - Business Description 25
Cytomedix, Inc. - SWOT Analysis 26
SWOT Analysis - Overview 26
Cytomedix, Inc. - Strengths 26
Strength - Focused Research & Development 26
Strength - Broad Patent Portfolio 26
Strength - Product Portfolio 26
Cytomedix, Inc. - Weaknesses 26
Weakness - Reliance on Third Parties 26
Cytomedix, Inc. - Opportunities 27
Opportunity - Market Potential: Chronic Wounds 27
Opportunity - Application for Expanded Indications 27
Opportunity - Growth Initiatives 27
Opportunity - Business Reorganization 27
Cytomedix, Inc. - Threats 27
Threat - Rapid Technological Change 27
Threat - Competitive Environment 28
Threat - Tightening of FDA’s Regulatory Oversight 28
Cytomedix, Inc. - Key Competitors 29
Section 3 – Company Financial Ratios 30
Financial Ratios - Capital Market Ratios 30
Financial Ratios - Annual Ratios 30
Performance Chart 32
Financial Performance 32
Financial Ratios - Interim Ratios 33
Financial Ratios - Ratio Charts 34
Section 4 – Company’s Lifesciences Financial Deals and Alliances 35
Cytomedix, Inc., Medical Equipment, Deals By Year, 2008 to YTD 2014 35
Cytomedix, Inc., Medical Equipment, Deals By Type, 2008 to YTD 2014 36
Cytomedix, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 37
Cytomedix, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 38
Cytomedix, Inc., Recent Deals Summary 39
Section 5 – Company’s Recent Developments 40
Cytomedix, Inc., Recent Developments 40
Apr 07, 2014: Cytomedix Announces Appointment of Andrew Cohen as Vice President of Marketing 40
Apr 03, 2014: Cytomedix Announces Receipt of USPTO Allowance for Patent Covering Use of ALDH Bright Cells in Stroke 40
Mar 31, 2014: Cytomedix Reports 2013 Fourth Quarter and Full Year Financial Results 41
Mar 31, 2014: Cytomedix Announces Senior Management Appointments 42
Nov 12, 2013: Cytomedix Reports Third Quarter 2013 Financial Results 43
Sep 17, 2013: Cytomedix Announces Strategic Reorganization of Research and Development Operations 45
Aug 07, 2013: Cytomedix Announces Second Quarter 2013 Financial Results and Commercial Partnership for Angel Technology 45
Aug 02, 2013: Cytomedix to Host Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013 47
May 17, 2013: Cytomedix To Present At World Stem Cells & Regenerative Medicine Congress 2013 47
May 09, 2013: Cytomedix Reports Revenue Of $2.3m In Q1 2013 47
Section 6 – Appendix 50
Methodology 50
Ratio Definitions 50
About GlobalData 54
Contact Us 54
Disclaimer 54
List Of Tables
List of Tables
Cytomedix, Inc., Key Facts 5
Cytomedix, Inc., Key Employees 6
Cytomedix, Inc., Key Employee Biographies 7
Cytomedix, Inc., Major Products and Services 8
Cytomedix, Inc., Number of Pipeline Products by Therapy Area 9
Cytomedix, Inc., Number of Pipeline Products by Development Stage 10
Cytomedix, Inc., Pipeline Products By Therapy Area and Development Phase 11
Cytomedix, Inc. Pipeline Products by Equipment Type 12
Cytomedix, Inc. Number of Pipeline Products by Development Stage 13
Cytomedix, Inc. Pipeline Products by Development Stage 14
Cytomedix, Inc., History 15
Cytomedix, Inc., Subsidiaries 24
Cytomedix, Inc., Key Competitors 29
Cytomedix, Inc., Ratios based on current share price 30
Cytomedix, Inc., Annual Ratios 30
Cytomedix, Inc., Interim Ratios 33
Cytomedix, Inc., Medical Equipment, Deals By Year, 2008 to YTD 2014 35
Cytomedix, Inc., Medical Equipment, Deals By Type, 2008 to YTD 2014 36
Cytomedix, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 37
Cytomedix, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 38
Cytomedix, Inc., Recent Deals Summary 39
Currency Codes 50
Capital Market Ratios 50
Equity Ratios 51
Profitability Ratios 51
Cost Ratios 52
Liquidity Ratios 52
Leverage Ratios 53
Efficiency Ratios 53
List Of Figures
List of Figures
Cytomedix, Inc., Pipeline Products by Therapy Area 9
Cytomedix, Inc., Pipeline Products by Development Phase 10
Cytomedix, Inc. Pipeline Products by Development Stage 13
Cytomedix, Inc., Performance Chart (2008 - 2012) 32
Cytomedix, Inc., Ratio Charts 34
Cytomedix, Inc., Medical Equipment, Deals By Year, 2008 to YTD 2014 35
Cytomedix, Inc., Medical Equipment, Deals by Type, 2008 to YTD 2014 36
Cytomedix, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 37
Cytomedix, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 38
